Sanfilippo syndrome: Overall review

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pediatrics International

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ped.12636PMID 25851924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UvA-DARE ( Digital Academic Repository ) Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

  2017cited by this paper
• Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III.

  2015cited by this paper
• Repeated Administrations of Human Umbilical Cord Blood Cells Improve Disease Outcomes in a Mouse Model of Sanfilippo Syndrome Type III B

  2014cited by this paper
• Natural history of Sanfilippo syndrome type A

  2014cited by this paper
• Assessment of Sleep in Children with Mucopolysaccharidosis Type III

  2014cited by this paper
• Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease

  2014cited by this paper
• Mucopolysaccharidosis Type IIIA presents as a variant of Klüver–Bucy syndrome

  2013cited by this paper
• Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease

  2013cited by this paper
• Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI

  2013cited by this paper
• Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID)

  2013cited by this paper
• Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice

  2013cited by this paper
• High prevalence of femoral head necrosis in Mucopolysaccharidosis type III (Sanfilippo disease): a national, observational, cross-sectional study.

  2013cited by this paper
• Natural history of Sanfilippo syndrome in Spain

  2013cited by this paper
• Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

  2013cited by this paper
• Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders

  2013cited by this paper
• High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system.

  2013cited by this paper
• Assay of heparan-N-sulfamidase in dried leukocytes impregnated in filter paper: a new tool for the identification of mucopolisaccharidosis IIIA and potentially other lysosomal disorders.

  2013cited by this paper
• Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB

  2012cited by this paper
• Anaesthesia and airway management in mucopolysaccharidosis

  2012cited by this paper
• Dental Findings and Management in a Mucopolysaccharidosis Type IIIB Patient.

  2012cited by this paper
• Abnormal Gangliosides are Localized in Lipid Rafts in Sanfilippo (MPS3a) Mouse Brain

  2012cited by this paper
• Treatment of Lysosomal Storage Disorders

  2012cited by this paper
• Genistein in Sanfilippo disease: A randomized controlled crossover trial

  2012cited by this paper
• The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.

  2012cited by this paper
• Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease.

  2012cited by this paper
• Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.

  2012cited by this paper
• Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies.

  2011cited by this paper
• Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)

  2011cited by this paper
• Musculoskeletal Manifestations of Sanfilippo Syndrome (Mucopolysaccharidosis Type III)

  2011cited by this paper
• Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece

  2011cited by this paper
• Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

  2011cited by this paper
• Molecular analysis of Sanfilippo syndrome type C in Spain: seven novel HGSNAT mutations and characterization of the mutant alleles

  2011cited by this paper
• Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

  2010cited by this paper
• Restoration of central nervous system α‐N‐acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno‐associated viral type 2 vector delivery

  2010cited by this paper
• Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations b

  2010cited by this paper
• Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.

  2010cited by this paper
• Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones

  2010cited by this paper
• Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations

  2010cited by this paper
• Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

  2010cited by this paper
• Serum MIP-1 α level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice

  2010cited by this paper
• THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE

  2010cited by this paper
• Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I

  2010cited by this paper
• Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.

  2010cited by this paper
• Intracranial gene delivery of LV‐NAGLU vector corrects neuropathology in murine MPS IIIB

  2009cited by this paper
• On-line separations combined with MS for analysis of glycosaminoglycans.

  2009cited by this paper
• Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.

  2008cited by this paper
• Heparin cofactor II-thrombin complex: a biomarker of MPS disease.

  2008cited by this paper
• Sanfilippo syndrome: A mini-review

  2008cited by this paper
• Stability of urinary glycosaminoglycans in patients with mucopolysaccharidoses.

  2008cited by this paper
• Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry.

  2007cited by this paper
• Scoring Evaluation of the Natural Course of Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

  2007cited by this paper
• Bone marrow transplantation in patients with storage diseases: a developing country experience.

  2006cited by this paper
• Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome).

  2006cited by this paper
• Enzyme replacement for lysosomal diseases.

  2006cited by this paper
• Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C).

  2006cited by this paper
• Prenatal diagnosis of Sanfilippo syndrome

  2005cited by this paper
• Cumulative incidence rates of the mucopolysaccharidoses in Germany

  2005cited by this paper
• Transplantation of Human Umbilical Cord Blood Cells Benefits an Animal Model of Sanfilippo Syndrome Type B

  2005cited by this paper
• Prevalence of lysosomal storage diseases in Portugal

  2004cited by this paper
• Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation

  2004cited by this paper
• Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters

  2004cited by this paper
• The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations.

  2004cited by this paper
• Localisation of a gene for mucopolysaccharidosis IIIC to the pericentromeric region of chromosome 8

  2004cited by this paper
• Incidence of the mucopolysaccharidoses in Western Australia

  2003cited by this paper
• Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications

  2001cited by this paper
• Mucopolysaccharidoses and Oligosaccharidoses

  2000cited by this paper
• Bone marrow transplantation in mucopolysaccharidosis type IIIA: A comparison of an early treated patient with his untreated sibling

  1999cited by this paper
• The frequency of lysosomal storage diseases in The Netherlands

  1999cited by this paper
• Human Gene Mutation Database

  1996cited by this paper
• Neurology of hereditary metabolic diseases of children

  1996cited by this paper
• A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type A (MPS IIIA)

  1996cited by this paper
• Inborn Metabolic Diseases: Diagnosis and Treatment

  1995cited by this paper
• Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplantation and successful engraftment

  1995cited by this paper
• Bone marrow transplantation for Sanfilippo disease type B

  1992cited by this paper
• A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulphatases.

  1992cited by this paper
• Neurology of Hereditary Metabolic Diseases of Children

  1983cited by this paper
• Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate.

  1982cited by this paper
• Sanfilippo syndrome type C: deficiency of acetyl-CoA:alpha-glucosaminide N-acetyltransferase in skin fibroblasts.

  1978cited by this paper
• The Mucopolysaccharidoses

  1976cited by this paper
• Mental retardation associated with acid mucopolysacchariduria (heparitin sulfate type)

  1963cited by this paper

• Letter: Fluoxetine for Behavioral Problems in an 8-Year-Old with Mucopolysaccharidosis IIIA.

  2026cites this paper
• TFEB, FOXO3 and TLR4 in resveratrol-induced autophagy in a mucopolysaccharidosis IIIB mouse model.

  2026cites this paper
• Sanfilippo syndrome type A with acute metabolic acidosis: a case report of the first documented SGSH c.571G > A homozygous mutation.

  2026cites this paper
• A Rare Compound Heterozygous NAGLU Gene Mutation in Two Siblings with Mucopolysaccharidosis type Iiib

  2025cites this paper
• The Neuroimmune Landscape of the Lysosomal Storage Disorder Sanfilippo Syndrome

  2025cites this paper
• Mucopolysaccharidoses—What Clinicians Need to Know: A Clinical, Biochemical, and Molecular Overview

  2025cites this paper
• Clinical, biochemical, and molecular characteristics of Sanfilippo a syndrome (MPS IIIA) in a cohort of Egyptian patients

  2025influential citation
• Evaluating Patients With Mucopolysaccharidosis Type III: A Scoping Review on Diagnostic and Follow-Up Approaches.

  2025cites this paper
• VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance

  2025cites this paper
• Mucopolysaccharidosis type III (Sanfilippo syndrome): a rare case report

  2025cites this paper
• The first case of sick sinus syndrome with an adult Sanfilippo A syndrome: a case report with review of literature

  2025cites this paper
• Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

  2024cites this paper
• Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review

  2024cites this paper
• Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB

  2024influential citation
• Genetic features of patients with MPS type IIIB: Description of five pathogenic gene variations.

  2024cites this paper
• The Role of the Gut Microbiota in Sanfilippo Syndrome’s Physiopathology: An Approach in Two Affected Siblings

  2024cites this paper
• Behaviours and psychological symptoms of childhood dementia: two cases of psychosocial interventions

  2024influential citation
• Tandem mass spectrometry-based assay for heparan-N-sulphatase in paediatric CSF: A potential pharmacodynamic biomarker for mucopolysaccharidosis type IIIA therapy.

  2024cites this paper
• Structure and mechanism of lysosome transmembrane acetylation by HGSNAT

  2024cites this paper
• Exploring Molecular and Phenotypic Characteristics of NAGLU Arg234Gly and Asp312Asn Variants

  2024cites this paper
• Clinical and neuroimaging characterization of the first frontotemporal dementia family carrying the MAPT p.K298E mutation

  2024cites this paper
• Causes of death in mucopolysaccharidoses.

  2024cites this paper
• Novel gene-specific Bayesian Gaussian mixture model to predict the missense variants pathogenicity of Sanfilippo syndrome

  2024cites this paper
• AAV gene replacement therapy for treating MPS IIIC: Facilitating bystander effects via EV‐mRNA cargo

  2024cites this paper
• Zebrafish models of Mucopolysaccharidosis types IIIA, B, & C show hyperactivity and changes in oligodendrocyte state

  2024cites this paper
• Goat’s Genetic Disorder: Mucoplysaccharidosis III D (MPS III D)

  2023cites this paper
• Lysosomal storage disorders: Clinical and therapeutic aspects.

  2023cites this paper
• Mucopolysaccharidosis type IIIC in chinese mainland: clinical and molecular characteristics of ten patients and report of six novel variants in the HGSNAT gene

  2023cites this paper
• Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.

  2023cites this paper
• Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape

  2023cites this paper
• Clinical, biochemical, and molecular characterization of mucopolysaccharidosis type III in 34 Egyptian patients

  2023influential citation
• Expanding the phenotypic and genotypic spectrum of patients with HGSNAT-related retinopathy

  2023influential citation
• Biochemical diagnosis of Sanfilippo disorder types A and B

  2023cites this paper
• Experimental Models of CNS Disorders Related to Lysosomal Storage Diseases

  2023cites this paper
• Late‐onset mucopolysaccharidosis type IIIA mimicking Usher syndrome

  2023cites this paper
• Experimental Models of CNS Deficits in Lysosomal Storage Diseases

  2023cites this paper
• Neurological, neurobehavioral, and radiological alterations in patients with mucopolysaccharidosis III (Sanfilippo's syndrome) in Brazil

  2022cites this paper
• Sanfilippo syndrome: consensus guidelines for clinical care

  2022influential citation
• A Novel Mutation in the NAGLU (N-Acetyl-Alpha-Glucosaminidase) Gene Associated With Mucopolysaccharidosis Type III-B in a Saudi Girl

  2022cites this paper
• Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach

  2022cites this paper
• Immunoglobulin-G subclass pattern among children with mucopolysaccharidosis attending the genetic clinic of Alexandria University Children’s Hospital

  2022cites this paper
• Brain transplantation of genetically corrected Sanfilippo type B neural stem cells induces partial cross-correction of the disease

  2022cites this paper
• Unusual Clinical Manifestations in a Mexican Patient with Sanfilippo B Syndrome

  2022cites this paper
• A case report of Sanfilippo syndrome – the long way to diagnosis

  2022influential citation
• Mi hija, mi vida / tu vivras ma fille (2018) de Gabriel Aghion, de la medicina familiar a la biotecnología

  2022cites this paper
• A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B

  2022cites this paper
• ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications.

  2021influential citation
• Gastrointestinal Manifestations in Mucopolysaccharidosis Type III: Review of Death Certificates and the Literature

  2021cites this paper
• Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders

  2021cites this paper
• Clinical and genetic features of 13 patients with mucopolysaccarhidosis type IIIB: Description of two novel NAGLU gene mutations

  2021cites this paper
• [Intestinal lymphangiectasia in a patient with Sanfilippo B syndrome].

  2021cites this paper
• Differences in MPS I and MPS II Disease Manifestations

  2021cites this paper
• Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB.

  2021cites this paper
• The Future of Newborn Screening for Lysosomal Disorders.

  2021cites this paper
• A GH89 human α-N-acetylglucosaminidase (hNAGLU) homologue from gut microbe Bacteroides thetaiotaomicron capable of hydrolyzing heparosan oligosaccharides

  2021cites this paper
• Schizophreniform presentation and abrupt neurologic decline in a patient with late-onset mucopolysaccharidosis type IIIB.

  2021cites this paper
• Early diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome) in the practice of a pediatrician

  2021cites this paper
• Hearing Loss in Mucopolysaccharidoses

  2020cites this paper
• Cerebellar tumour-like aggregate of glycosaminoglycans in a MPS IIIB patient: a case report

  2020cites this paper
• Neuronal and Astrocytic Differentiation from Sanfilippo C Syndrome iPSCs for Disease Modeling and Drug Development

  2020cites this paper
• MUCOPOLYSACCHARIDOSIS TYPE-II: A RARE CASE OF HUNTER SYNDROME

  2020cites this paper
• A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.

  2020cites this paper
• Otorhinolaryngological Findings in Patients from Southwestern Colombia with Clinical, Enzymatic and Molecular Diagnosis of Mucopolysaccharidosis II, IV-A and VI

  2020cites this paper
• Murine cellular model of mucopolysaccharidosis, type IIIB (MPS IIIB) - A preliminary study with particular emphasis on the non-oxidative l-cysteine metabolism.

  2020cites this paper
• Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.

  2020cites this paper
• A RARE CASE OF SANFILIPPO SYNDROME TYPE “C”

  2020cites this paper
• Enzyme therapy: a forerunner in catalyzing a healthy society?

  2020cites this paper
• Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions

  2020influential citation
• Psychiatric Symptoms Associated with Inborn Errors of Metabolism

  2020cites this paper
• Identification of a novel mutation in the SGSH gene in an Indian child with Sanfilippo syndrome type IIIA

  2020cites this paper
• Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome).

  2020cites this paper
• Failures of Endochondral Ossification in the Mucopolysaccharidoses

  2020cites this paper
• Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches

  2020influential citation
• MUCOPOLYSACARIDOSIS TYPE IIIB MISDIAGNOSED AS AN AUTISTIC SPECTRUM DISORDER: A CASE REPORT AND LITERATURE REVIEW

  2020cites this paper
• Development of a Clinical Algorithm for the Early Diagnosis of Mucopolysaccharidosis III

  2020cites this paper
• Coinheritance of novel mutations in NAGLU causing mucopolysaccharidosis type IIIB and in DDHD2 causing spastic paraplegia54 in a Turkish family.

  2020cites this paper
• Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment

  2020cites this paper
• Synophrys: The societal implications of the bad ol' unibrow.

  2020cites this paper
• DIAGNOSIS OF CHILDREN WITH SANFILIPPO DISEASE – PSYCHOLOGICAL, SOCIAL AND MOTOR ASSESSMENT

  2020cites this paper
• Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III

  2020cites this paper
• The mucopolysaccharidoses

  2020cites this paper
• Prediction of the Effect of Naturally Occurring Missense Mutations on Cellular N-Acetyl-Glucosaminidase Enzymatic Activity

  2019cites this paper
• An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene

  2019cites this paper
• Assessment of predicted enzymatic activity of alpha-N-acetylglucosaminidase (NAGLU) variants of unknown significance for CAGI 2016

  2019cites this paper
• New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.

  2019cites this paper
• Ophthalmological Findings in Mucopolysaccharidoses

  2019influential citation
• Assessment of predicted enzymatic activity of α‐N‐acetylglucosaminidase variants of unknown significance for CAGI 2016

  2019cites this paper
• Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data

  2019cites this paper
• Effect of glycosaminoglycans accumulation on the non-oxidative sulfur metabolism in mouse model of Sanfilippo syndrome, type B.

  2019influential citation
• Sanfilippo syndrome

  2019cites this paper
• Human Mutation

  2019cites this paper
• Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA

  2019cites this paper
• Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B

  2018cites this paper
• Vulnerabilidade à cárie dentária em indivíduos diagnosticados com doenças genéticas raras

  2018cites this paper
• Emerging Therapies For the Treatment of Mucopolysaccharidosis Type III

  2018cites this paper
• BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis

  2018cites this paper
• A novel mutation of SGSH and clinical features analysis of mucopolysaccharidosis type IIIA

  2018cites this paper
• A novel frameshift deletion in NAGLU causing sanfilipo type III‐B in an Indian family

  2018cites this paper
• Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders.

  2018cites this paper
• Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice

  2018cites this paper